Clinical Trials · NCT06633783
A Phase III Study Comparing the Weight Loss Effects of Semaglutide Injection and Wegovy®
- Phase
- Phase 3
- Recruitment status
- Not Yet Recruiting
- Sponsor
- Hangzhou Jiuyuan Gene Engineering Co. Ltd.,
- Enrollment
- 370
- Start date
- Oct 2024
- Locations
- 14 sites, China
- Primary endpoint
- Change in body weight